Nereida Correa, MD
Obstetrics & Gynecology · Bronx, NYNPI 1154433209
Payments from drug & device makers
Across 88 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$565
- AbbVie$407
- Merck$311
- Shield Therapeutics Inc$268
- Daiichi Sankyo Inc.$181
- Myovant Sciences Inc.$163
- plus $838 from 16 others
What the payments were for
- Food & beverage$2,36687%
- Education$36813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 12 | $565 |
| AbbVie(2 entities) | 14 | $407 |
| Merck | 11 | $311 |
| Shield Therapeutics Inc | 8 | $268 |
| Daiichi Sankyo Inc. | 9 | $181 |
| Myovant Sciences Inc. | 7 | $163 |
| Mayne Pharma Commercial LLC | 6 | $131 |
| Gilead | 2 | $119 |
| Novartis | 1 | $106 |
| AstraZeneca | 1 | $97 |
| Sage Therapeutics, LLC | 1 | $97 |
| Therapeuticsmd, Inc. | 3 | $55 |
| Coopersurgical, Inc. | 2 | $50 |
| Organon | 3 | $41 |
| Boston Scientific | 1 | $34 |
| Pfizer | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Mylan Pharmaceuticals Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Evofem Biosciences, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
| Millicent US Inc | 1 | $13 |
How this compares
$2,734 in reported general payments places this provider in the 85th percentile of 2,673 obstetrics & gynecology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 16 | $1,599 |
| Estradiol | 44 | $1,417 |
| Terconazole | 33 | $877 |
| Nystatin | 49 | $614 |
| ValacyclovirValacyclovir Hcl | 17 | $158 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Bronx
- Marina FrimerBronx$8.5M
- Nicole NevadunskyBronx$2.5M
- Jessica AtrioBronx$752K
- Mark LevieBronx$216K
- Magdy MikhailBronx$96K
- Ja Hyun ShinBronx$77K
- Jin Hee KimNew York$1M
- Carolyn WesthoffNew York$935K
- Mary PolanNew York$862K
- Mark MartensAuburn$561K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.